• Annual revenue up 88% with a 50% increase in the last quarter
• Cash position of $1.48M and a $5M funding facility signed in July
• Expansion into Ex-US markets with distribution partners in Asia, India, and the Middle East
• Successful clinical study showing improved patient outcomes and surgeon feedback
• Development of novel nerve repair and regeneration products

ReNerve Ltd's Q4 FY26 presentation highlights significant financial growth, with annual revenue up 88% and a 50% increase in the last quarter. The company's cash position stands at $1.48M, bolstered by a $5M funding facility signed in July. ReNerve has successfully expanded into Ex-US markets, establishing distribution partners in Asia, India, and the Middle East. The presentation emphasizes positive outcomes from the 'Align' clinical study, showcasing improved patient results and strong surgeon feedback. The company is also advancing its product pipeline, with nerve conduits and protector ranges entering validation and commercial production phases. The presentation underscores the potential of the nerve repair biomaterials market, projected to grow at a CAGR of 17.8% to USD$6.19Bn by 2031.

Annual revenue up 88%, Q4 revenue up 50%, cash position $1.48M, $5M funding facility

ReNerve is focused on continued sales expansion, launching new products, and completing clinical studies. The company aims to capitalize on the growing nerve repair biomaterials market, estimated to be worth over USD$6.19Bn by 2031.